Australia markets open in 7 hours 1 minute
  • ALL ORDS

    7,537.90
    -165.00 (-2.14%)
     
  • AUD/USD

    0.7239
    -0.0029 (-0.40%)
     
  • ASX 200

    7,248.20
    -155.50 (-2.10%)
     
  • OIL

    70.48
    -1.49 (-2.07%)
     
  • GOLD

    1,762.60
    +11.20 (+0.64%)
     
  • BTC-AUD

    60,582.10
    -5,525.75 (-8.36%)
     
  • CMC Crypto 200

    1,097.78
    -36.61 (-3.23%)
     

Global Epilepsy Drugs Market (2020 to 2027) - Featuring UCB, Eisai, H. Lundbeck and GW Pharmaceuticals

·4-min read

Dublin, Sept. 15, 2021 (GLOBE NEWSWIRE) -- The "Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Globally, millions of people are affected by neurological disorders. In that, over 80% of the death takes place in the low and middle-income countries. Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages. This disease is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. Patients who have epilepsy suffer from sudden behavioral changes, loss of consciousness and severe emotional distress. According to the World Health Organization (WHO), around 50 million people have epilepsy worldwide. Epilepsy is a common serious, and about 2.4 million new cases are diagnosed annually.

Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market. Increasing R&D investment and the launch of extended-release formulations are further expected to fuel the market growth. According to the publisher, the Global Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027.

Globally, United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after stroke, migraine, and Alzheimer's disease. About one percent of Americans have some form of epilepsy, and nearly four percent (which is equal to 1 in 26) will develop epilepsy at some point in their lives. Thus, there is a rising demand for effective treatment in the US, significantly boosting the growth of the epilepsy drug market.

Additionally, China, India, and Brazil were among the countries with a higher proportion of the population suffering from the condition. To minimize the burden of this disease and facilitate the availability of better treatment options, governments from various countries across the world are providing active support. According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).

The global epilepsy drugs market is segmented into First Generation, Second Generation, Third Generation, Others. The third Generation holds the largest market share; the major factors responsible for the growth of the third generation segment include the launch of highly efficacy drugs with the enhanced mechanism of action, fewer side effects and the awaited launch of new pipeline medicines. Third-generation drugs such as Vimpat, Briviact and others have penetrated the worldwide market considerably and proven to be quite effective in treating epilepsy.

On the other hand, the second-generation antiepileptic drug class, including Keppra, Fycompa and Briviact. They dominated the market due to their large tolerability and safety due to the launch of highly potent drugs, which apply novel techniques mechanisms of action. Worldwide Epilepsy Drugs Market Size was US$ 7.1 Billion in 2020.

Top players such as Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. of Epilepsy Drugs Market focus on introducing medications that have lesser side-effects to the patients. Besides, companies are also focused on improving the potentiality of the drugs to control the symptoms of epilepsy effectively. In 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China to treat patients aged 12 years and more adults with partial-onset seizures.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Epilepsy Drugs Market

6. Market Share - Global Epilepsy Drugs
6.1 By Country
6.2 By Drugs Category
6.3 By Drugs

7. Country - Global Epilepsy Drugs Market Analysis
7.1 United States
7.2 United Kingdom
7.3 France
7.4 Germany
7.5 Italy
7.6 Spain
7.7 India
7.8 China
7.9 Japan

8. Drugs Category - Global Epilepsy Drugs Market Analysis
8.1 First Generation
8.2 Second Generation
8.3 Third Generation
8.4 Others

9. Drugs - Global Epilepsy Drugs Market Analysis
9.1 Vimpat (Lacosamide)
9.2 Keppra (Levetiracetam)
9.3 Sabril (Vigabatrin)
9.4 Onfi (Clobazam)
9.5 Fycompa
9.6 Briviact (Brivaracetam)
9.7 Epidiolex
9.8 Cenobamate (YKP3089)
9.9 Others

10. Company Analysis
10.1 Eisai Co., Ltd.
10.1.1 Overview
10.1.2 Recent Development
10.1.3 Sales Analysis
10.2 UCB Inc.
10.2.1 Overview
10.2.2 Recent Development
10.2.3 Sales Analysis
10.3 H. Lundbeck A/S
10.3.1 Overview
10.3.2 Recent Development
10.3.3 Sales Analysis
10.4 GW Pharmaceuticals Plc.
10.4.1 Overview
10.4.2 Recent Development
10.4.3 Sales Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ebuvje

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting